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Objective: To develop concise, up-to-date, patient-focused, evidence-based, expert consensus guidelines
for the management of knee osteoarthritis (OA), intended to inform patients, physicians, and allied
healthcare professionals worldwide.
Method: Thirteen experts from relevant medical disciplines (primary care, rheumatology, orthopedics,
physical therapy, physical medicine and rehabilitation, and evidence-based medicine), three continents
and ten countries (USA, UK, France, Netherlands, Belgium, Sweden, Denmark, Australia, Japan, and
Canada) and a patient representative comprised the Osteoarthritis Guidelines Development Group
(OAGDG). Based on previous OA guidelines and a systematic review of the OA literature, 29 treatment
modalities were considered for recommendation. Evidence published subsequent to the 2010 OARSI
guidelines was based on a systematic review conducted by the OA Research Society International (OARSI)
evidence team at Tufts Medical Center, Boston, USA. Medline, EMBASE, Google Scholar, Web of Science,
and the Cochrane Central Register of Controlled Trials were initially searched in ﬁrst quarter 2012 and
last searched in March 2013. Included evidence was assessed for quality using Assessment of Multiple
Systematic Reviews (AMSTAR) criteria, and published criticism of included evidence was also considered.
To provide recommendations for individuals with a range of health proﬁles and OA burden, treatment
recommendations were stratiﬁed into four clinical sub-phenotypes. Consensus recommendations were
produced using the RAND/UCLA Appropriateness Method and Delphi voting process. Treatments were
recommended as Appropriate, Uncertain, or Not Appropriate, for each of four clinical sub-phenotypes
and accompanied by 1e10 risk and beneﬁt scores.
Results: Appropriate treatment modalities for all individuals with knee OA included biomechanical in-
terventions, intra-articular corticosteroids, exercise (land-based and water-based), self-management and
education, strength training, and weight management. Treatments appropriate for speciﬁc clinical sub-: T.E. McAlindon, Department of Rheumatology, Tufts Medical Center, 800 Washington Street, Box 406, Boston,
.org (T.E. McAlindon), nigel.arden@ndorms.ox.ac.uk (N.K. Arden), francis.berenbaum@sat.aphp.fr (F. Berenbaum), s.
a), gillian.hawker@wchospital.ca (G.A. Hawker), yhenrotin@ulg.ac.be (Y. Henrotin), david.hunter@sydney.edu.au (D.
chi), kwoh@arthritis.arizona.edu (K. Kwoh), stefan.lohmander@med.lu.se (S. Lohmander), francois.rannou@cch.aphp.fr
wood@warwick.ac.uk (M. Underwood).
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T.E. McAlindon et al. / Osteoarthritis and Cartilage 22 (2014) 363e388364phenotypes included acetaminophen (paracetamol), balneotherapy, capsaicin, cane (walking stick),
duloxetine, oral non-steroidal anti-inﬂammatory drugs (NSAIDs; COX-2 selective and non-selective), and
topical NSAIDs. Treatments of uncertain appropriateness for speciﬁc clinical sub-phenotypes included
acupuncture, avocado soybean unsaponﬁables, chondroitin, crutches, diacerein, glucosamine, intra-
articular hyaluronic acid, opioids (oral and transdermal), rosehip, transcutaneous electrical nerve stim-
ulation, and ultrasound. Treatments voted not appropriate included risedronate and electrotherapy
(neuromuscular electrical stimulation).
Conclusion: These evidence-based consensus recommendations provide guidance to patients and prac-
titioners on treatments applicable to all individuals with knee OA, as well as therapies that can be
considered according to individualized patient needs and preferences.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) of the knee is a major cause of pain and lo-
comotor disability worldwide. In January 2010, the OA Research
Society International (OARSI) published an update to their
evidence-based, consensus recommendations for the treatment of
OA of the hip and knee1. The 2010 guidelines update followed two
previous OARSI guidelines statements2,3 and included systematic
reviews (SRs) of the evidence for relevant therapies and critical
appraisals of existing guidelines. Since the publication of the 2010
OARSI guidelines, the evidence base on knee OA treatment has
evolved. This guidelines statement aims to incorporate evidence
from these recent publications, in addition to the best-available
previously published research, to assess where previous treatment
recommendations should be modiﬁed or expanded to include new
OA treatments. Because clinical considerations and availability of
evidence between knee OA and hip OA treatments differ, the pre-
sent guidelines sought to focus speciﬁcally on treatment of primary
OA of the knee.
For the present guidelines, we endeavored to enhance the
applicability of treatment recommendations by stratifying for
relevant co-morbidities, and for the presence of OA in joints other
than the knee(s). To synthesize the scientiﬁc literature and expert
opinion, we adopted the RAND/University of California, Los Angeles
Appropriateness method4 and used a modiﬁed Delphi method to
achieve expert consensus closely integrated with empirical
evidence.
This statement updates the previous OARSI recommendations,
incorporating literature published between January 2009 and
March 2013, to scrutinize the safety and efﬁcacy of new therapies
for OA and reexamine existing therapies in light of recent evidence.
These recommendations are intended to be used in conjunction
with individual patient and physician’s values and judgments to
optimize OA treatment for different needs. These guidelines are
intended for use by practitioners internationally, based on expert
views of the relative safety and efﬁcacy of available treatments for
OA, irrespective of healthcare reimbursement policies or popular
treatment practices.Methodology
Literature search
Our strategy was to build on the prior OARSI literature review
and guidelines by searching for meta-analyses, SRs and randomized
controlled trials (RCTs) in the period subsequent to the 2010
guidelines search. The initial literature search was conducted in the
ﬁrst quarter of 2012, and was based on treatments from the OARSI
2010 guidelines in addition to new treatments proposed by the
Osteoarthritis Guidelines Development Group (OAGDG). The search
was last updated in March 2013.We deployed electronic searches in Medline, EMBASE, Google
Scholar, Web of Science, and the Cochrane Central Register of
Controlled Trials using relevant subject headings and keywords and
then hand-searched the reference lists of all retrieved studies and
abstracts presented at pertinent scientiﬁc meetings. Publications
eligible for inclusion in our literature summary were (1) the most
current SRs and/or meta-analyses and (2) any randomized clinical
trials published subsequent to those SRs. If multiple SRs were
published in a similar time period, all were included. If no SRs or
meta-analyses were available, all published RCTs were included.
Literature summary
Our approach to summation of the evidence was to update the
literature summary for the prior recommendations with high-
quality evidence that emerged subsequent to its publication in
2010. We selected the best-available evidence to inform guidelines
development. Meta-analyses, SRs and RCTs were considered to be
the highest level of evidence. The value of meta-analyses for a
literature synthesis is that they provide insight across the range of
available RCTs on a topic as well as forest plots, sensitivity analyses
and pooled results. The data extraction team produced a summary
for each intervention that included description of the study
methodology with full citations, any reported safety information,
and relevant outcomes including effect sizes.
The quality and level of evidence available for each treatment
modality was graded according to the following:
Level/type of evidence: The highest level of available evidence
used (e.g., SR and/or most current RCT).
Quality of evidence: The methodological rigor of the highest
level of evidence used. Meta-analyses and SRs were assigned a
quality rating of “Good”, “Fair”, or “Poor” using the Assessment of
Multiple Systematic Reviews Tool (AMSTAR). The Cochrane Risk of
Bias Assessment Method was used to rate RCTs.
Estimated Effect Sizes: If the level of evidence listed above
included a meta-analysis, the Estimated Effect Size for pain versus
control was stated from that meta-analysis. Only pooled effect sizes
reported as a standardized mean difference (SMD) were reported.
Thus, the expert panel was informed with the prior OARSI
guideline publications, subsequent publications generated by the
literature search, and a literature summary (Bibliography available
as supplement). We provided the literature summary to the OAGDG
in August of 2012.
Composition of the expert panel
The OAGDG expert panel was composed of 13 voting members
and a patient advocate. This group was selected for its diverse
expertise and experience in OA management. The panel included
seven rheumatologists (NA, FB, GH, DH, KK, TM, FR), two orthopedic
surgeons (HK, SL), two physical therapists (SBZ, ER), one primary
care practitioner and clinical guidelines methodologist (MU), and
one physical therapy and rehabilitation specialist (YH). These
Table I
Stratiﬁcation into sub-phenotypes
OA joint type Knee-only OA: Symptomatic OA in one
or both knees only.
Multiple-joint OA*: Symptomatic OA of the
knee(s) in addition to other joints
(e.g., hip, hand, spine, etc).
Co-morbidities No co-morbidities: The individual with OA
has no pertinent co-morbid health concerns.
Co-morbidities: The individual with OA has
any of the following pertinent co-morbid
health concerns: diabetes; hypertension;
CV disease; renal failure; gastrointestinal (GI)
bleeding; depression; or physical impairment
limiting activity, including obesity.
 Moderate co-morbidity risky: The individual
with OA has any of the following pertinent
co-morbid health concerns: diabetes;
advanced age; hypertension; CV disease;
renal failure; GI complications; depression;
or physical impairment limiting
activity, including obesity.
 High co-morbidity risky: The individual
with OA has risk factors such as history
of GI bleed, myocardial infarction,
chronic renal failure, etc.
* Deﬁnes a clinical sub-phenotype. Recommendations refer to treatment of the
knee(s) in such individuals.
y For Oral NSAIDs (both non-selective and selective COX-2 inhibitors). Further
stratiﬁcation of risk categories was considered necessary for these treatments given
the important safety implications and substantial availability of safety data.
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practice, and also have expertise in clinical epidemiology and other
research methodology (Appendix 1).
Management of conﬂict of interest (COI)
At the request of the OARSI Ethics Committee, all members of the
OAGDG were required to complete a COI questionnaire to report
any potential conﬂicts including consulting, grant support, practice
revenue, intellectual property, etc. for each treatment (Appendix 1).
During initial rounds of voting, OAGDGmembers were instructed to
recuse themselves from voting on potentially conﬂicted treatment
modalities. At the April 2013 OARSI meeting, OAGDG members
updated disclosures and discussed these conﬂicts in personwith an
ethics committee member prior to the ﬁnal round of voting. The
Ethics Committee representative made a ﬁnal determination
regarding the level at which a potential conﬂict would disqualify an
OAGDG member from voting on each treatment. Final disclosure
and voting recusal results were twice distributed among the
OAGDG to verify their accuracy.
Role of funding source
This project was commissioned and funded by OARSI, yet was
developed independently by the OARSI Treatment Guidelines
Committee. The funding source did not participate in the literature
search; determination of study eligibility criteria; voting process;
data analysis or interpretation; or manuscript preparation. The
manuscript was reviewed and approved by OARSI’s Executive
Committee prior to release for public comment.
OARSI receives sponsorship from Bioiberica, EMD Serono,
Expanscience, Rottapharm/Madaus, Abbvie, Astellas, Bioventus,
Boston Imaging Core Lab (BICL), Chondrometrics, Fidia Pharma
USA, Flexion, Perceptive Informatics, Merck, Seikagaku, Servier, and
Zimmer. No direct medical industry support was used or requested
for guideline development. Guidelines development was a budg-
eted item in OARSI’s annual budget.
Formulation of recommendations
Role of the expert panel
The literature summary was released to the OAGDG in August of
2012. An updated literature summary was released in October 2012
to inform subsequent rounds of voting (Bibliography available in
supplement). Their role was to use the evidence base along with
their expert knowledge, to provide votes on the appropriateness of
each treatment modality, according to RAND/UCLA methodology4,
and also an assessment of beneﬁt and risk. The RAND/UCLA
methodology is a highly-established approach that was explicitly
developed to leverage expert opinion about interventions in situ-
ations where the evidence may be incomplete.
After an initial round of voting that occurred after viewing the
evidence, but prior to any discussion, the results were scrutinized
by the OAGDG using an online forum to generate discussion and
clariﬁcations. Subsequent rounds of voting were performed to with
further stratiﬁcations of treatment modalities (e.g., non-steroidal
anti-inﬂammatory drugs (NSAIDs) were split into non-selective,
selective COX-2 inhibitors, and topical) in October of 2012, March of
2013, and during the OAGDG’s face-to-facemeeting in April of 2013.
OA clinical sub-phenotypes. In order to enhance the speciﬁcity of
the treatment recommendations for individuals with varying
health proﬁles and OA burden, we deﬁned four clinical sub-
phenotypes (Table I). The rationale for these stratiﬁcations was
that co-morbidities and the presence of OA in other joints mightinﬂuence treatment choices. However, in all situations the voting
was focused on treatment of the knees, and not on treatment of
the non-knee joints. The OAGDG also decided on treatments that
might merit separate evaluation of symptomatic and structural
outcomes.
Voting and scoring. For each treatment modality, the OAGDG voted
on appropriateness using a nine-point scale (1e9), therapeutic
beneﬁt on a 10-point scale (1e10), and overall risk on a 10-point
scale (1e10).
According to the RAND/UCLA Appropriateness Method4, the
panelists ranked the appropriateness of each treatment on a nine-
point scale, in which a score in the range 1e3 is considered ‘inap-
propriate’, 4e6 ‘uncertain’, and 7e9 ‘appropriate’. We then pooled
these scores to generate a median appropriateness score for each
treatment according to patient sub-phenotype. In addition, accord-
ing to RAND/UCLA methodology, we classiﬁed the presence of
‘disagreement’ among the votes for a treatment modality if greater
than one-third fell in the opposite tertile to the median score [e.g., a
vote was considered in “Disagreement” if it received an “Appro-
priate” median vote (7) with ﬁve of 13 members voting ”Not
appropriate” (3)]. Finally, we classiﬁed a treatment as “Appro-
priate” if it received a median score of 7 without disagreement. A
treatment was classiﬁed as “Not appropriate” if it received a median
vote of 3 or lower without disagreement. A treatment receiving a
score between 3 and 6, or a treatment with disagreement, was
classiﬁed as “Uncertain”. An “Uncertain” recommendation can reﬂect
either the ambiguous state of current evidence or equivocal appro-
priateness either due to a moderately unfavorable risk proﬁle or to
limited efﬁcacy. However, the ‘uncertain’ classiﬁcation is not inten-
ded to be a negative recommendation or preclude use of that ther-
apy. Rather it indicates a role for physicianepatient interaction in
determining whether this treatment may have merit in the context
of their individual characteristics, co-morbidities and preferences.
Each OAGDG member also voted separately on the level of risk
and the level of beneﬁt associated with each treatment. Risk was
Fig. 1. Appropriate treatments summary.
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from 1 (no beneﬁt) to 10 (most beneﬁcial). The group’s mean risk
and beneﬁt scores [along with 95% conﬁdence intervals (CIs)] for
each treatment are plotted separately as bar graphs within the
guidelines statement (Appendix 2: Annotated Figure).
The OARSI guidelines report was drafted after a face-to-face
meeting and re-vote at the OAGDG meeting at the April 2013
OARSIWorld Congress. These guidelines provide recommendations
according to the median “appropriateness” scores voted upon by a
panel of expert physicians and researchers based on their knowl-
edge and the literature summary.
Figure 1 provides a summary of all treatments voted “Appro-
priate,” organized by clinical sub-phenotype. The OAGDG’s median
voting scores for appropriateness, uponwhich the recommendations
are based, are appended in a summary table (Appendix 3). Also
included are the OAGDG’s mean risk scores, beneﬁt scores, and
composite beneﬁt and risk scores for each treatment and clinical sub-
phenotype. The composite beneﬁt and risk score is the product of the
beneﬁt score (1e10) and the transposed risk score (where 1¼ highest
and 10 ¼ safety) yielding a range of 1 (worst) to 100 (best).
Public comment. The guidelines report draft was disseminated for
public comment between September 4th and 18th, 2013. At the
conclusion of the public comment period, public responses to the
guidelines report were distributed among the OAGDG in order to
formulate an appropriate response. Consistent with the OAGDG’s
prior procedures, it was determined that omission of any
research within the committee’s original literature summary
criteria would necessitate a re-vote on the treatment for which
evidence was omitted. Additional evidence for balneotherapy
and chondroitin was brought to the attention of the OAGDG
during public comment, resulting in an update of the evidence
report and a re-vote on each of these interventions by the
OAGDG expert panel. To incorporate the new chondroitinevidence, pooled analyses of pain and function outcomes were
conducted for randomized clinical trials of chondroitin in knee
OA. The balneotherapy evidence was considered too heteroge-
neous to permit pooled analysis. The ﬁnalized guidelines report
draft was submitted for publication following approval of the
OARSI Executive Committee.
Recommendations
Non-pharmacological interventions
Acupuncture
Recommendation:
 Uncertain
Rationale:
The efﬁcacy of acupuncture for peripheral joint OA has been
tested in numerous clinical trials. Trials using waiting list- or usual
care control groups, have generally found a clinically relevant
beneﬁt, but those using a sham-acupuncture have been less posi-
tive5. A recent pooled analysis of 16 RCTs found statistically sig-
niﬁcant beneﬁt of acupuncture in sham-controlled trials, though
this did not reach the investigators’ threshold for clinical
signiﬁcance5.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for
Pain (SMD): 0.28 (0.11e0.45)5.
Function (SMD): 0.28 (0.09e0.46)5.
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Recommendation:
 Appropriate: individuals with multiple-joint OA and relevant
co-morbidities
 Uncertain: individuals without relevant co-morbidities
 Uncertain: individuals with knee-only OA
Rationale:
Balneotherapy (deﬁned as the use of baths containing thermal
mineral waters) includes practices such as Dead Sea salt or mineral
baths, sulfur baths, and radon-carbon dioxide baths. Two 2009 SRs
and a 2009 RCT demonstrated beneﬁt of balneotherapy for pain
when compared with controls, but the methodologic quality of
trials was poor and both reviews concluded that additional large
and well-designed RCTs are needed6e8. No signiﬁcant safety con-
cerns were found to be associated with balneotherapy, though
reporting of adverse events was patchy among included trials7,9. In
the voting, balneotherapy was considered appropriate only for the
sub-phenotype with multiple-joint OA and co-morbidities, due to
paucity of treatment alternatives for that group.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Fair.
Estimated Effect Size for Pain or Function: Not available.Biomechanical interventions
Recommendation:
 Appropriate
Rationale:
We recommend use of biomechanical interventions as directed
by an appropriate specialist. A 2011 SR and three recent RCTs
evaluated the effectiveness of knee braces, knee sleeves, and foot
orthoses in conservative management of knee OA10e13. One review
suggested that knee braces and foot orthoses were effective in
decreasing pain, joint stiffness, and drug dosage and also improved
physical function, with insigniﬁcant adverse events10. The conclu-
sions were limited due to the heterogeneity and poor quality of
available evidence. Results regarding lateral wedge insoles varied,
with one RCT demonstrating no symptomatic or structural bene-
ﬁts11 and another asserting their appropriateness as a possible
alternative to valgus bracing for conservative medial knee OA
treatment12. One recent RCT found that variable-stiffness walking
shoes reduced adduction movement and pain and improved
function after 6 months of wear, though this beneﬁt was not sta-
tistically signiﬁcant when compared to constant-stiffness
footwear13.
Quality assessment:
Level of evidence: SR of RCTs and non-randomized clinical
trials.
Quality of evidence: Fair.
Estimated Effect Size for Pain or Function: Not available.Cane (walking stick)
Recommendation:
 Appropriate: knee-only OA
 Uncertain: multiple-joint OA
Rationale:
A single-blind RCT concluded that canes, in comparison with
usual disease management, could be used to diminish pain and
improve function and some aspects of quality of life in participants
with knee OA14. A substantial increase in energy expenditure in the
ﬁrst month of cane use was no longer a factor for concern by the
end of the second month. There was a lack of evidence regarding
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ment could be inappropriate for some such individuals, as cane use
to relieve knee pain may increase weight-bearing load on other
affected joints (e.g., contralateral hand and hip joints), though
further research is needed to conﬁrm this.
Quality assessment:
Level of overall evidence: Single-blind RCT.
Quality of overall evidence: Fair.
Estimated Effect Size for Pain or Function: Not available.Crutches
Recommendation:
 Uncertain
Rationale:
There is insufﬁcient evidence at this time to support the use of
crutches as an appropriate alternative to cane use.
Level of Evidence: Expert consensus of OAGDG.
Quality of evidence: No available trials.
Estimated Effect Size for Pain or Function: Not available.Electrotherapy/neuromuscular electrical stimulation
Recommendation:
 Not appropriate
Rationale:
A 2012 SR and meta-analysis demonstrated conﬂicting efﬁcacy
data for neuromuscular electrical stimulation and concluded that
additional studies were needed to determine the efﬁcacy of this
intervention15. A recent RCT showed no signiﬁcant additive effect of
electromyograph (EMG) biofeedback to strengthening exercise for
pain, function andmuscle strength in 40 participantswith kneeOA16.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Fair.
Estimated Effect Size for Pain or Function: Not available.Exercise (land-based)
Recommendation:
 Appropriate
Rationale:
Four recent meta-analyses found small but clinically relevant
short-term beneﬁts of land-based exercise for pain and physical
function in knee OA17e20. Meta-analyses investigating t’ai chi found
strong favorable beneﬁts of t’ai chi for improving pain and physical
function in individuals with knee OA21,22. The duration and type of
exerciseprograms included in thesemeta-analyses variedwidely, but
interventions included a combination of elements including strength
training, active range of motion exercise, and aerobic activity. Results
were generally positive among land-based exercise type, and did not
signiﬁcantly favor any speciﬁc exercise regimens17e20.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for
Pain (SMD): Ranges from 0.34 (0.19e0.49)17 to 0.63 (0.39e
0.87)21.
Function (SMD): 0.25 (0.03e0.48)17.
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Recommendation:
 Appropriate
Rationale:
A 2007 SR investigating water-based exercise in knee and hip
OA found small to moderate short-term beneﬁts for function and
quality of life, but only minor beneﬁts for pain23.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs and quasi-
randomized trials.
Quality of evidence: Good.
Estimated Effect Size for Pain or Function: Not available.Strength training
Recommendation:
 Appropriate
Rationale:
A 2011 meta-analysis and SR demonstrated moderate effect
sizes of strength training for reducing pain and improving physical
function compared with controls17. Strength training programs
primarily incorporate resistance-based lower limb and quadriceps
strengthening exercises. Both weight-bearing and non-weight-
bearing interventions were included, as well as group and indi-
vidual programs. Participants experienced similarly signiﬁcant
improvement with each of these programs.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for
Pain (SMD): 0.38 (0.23e0.54)17.
Function (SMD): 0.41 (0.17e0.66)17.
Self-management and education
Recommendation:
 Appropriate
Rationale:
A 2011 meta-analysis and a 2005 meta-analysis found moderate
beneﬁts of self-management programs for chronic musculoskeletal
pain conditions on measures of pain and disability24,25. Analysis of
arthritis-related disability showed only modest beneﬁt. Recent
randomized clinical trials indicated signiﬁcant clinical beneﬁts of
self-management26,27 and suggested feasibility of implementation
in primary care by means of group sessions28 and telephone-based
sessions29. Another RCT expressed reservations about the efﬁcacy
and practicality of such interventions30.
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Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Sizes for
Pain (SMD): Ranges from0.06 (0.02e0.10)25 to 0.29 (0.17e0.41)24.Transcutaneous electrical nerve stimulation (TENS)
Recommendation:
 Uncertain: knee-only OA
 Not appropriate: multiple-joint OA
Rationale:
A 2009 SR found inconclusive results regarding the effect of
TENS for pain relief in knee OA31. Due to the low methodological
quality and high heterogeneity of included trials, no effect size was
reported as a primary result. The review found no evidence to
suggest that TENS was unsafe. A recent RCT revealed no statistically
signiﬁcant difference for pain between TENS and a sham TENS
procedure32.
Quality assessment:
Level of evidence: SR of randomized or quasi-randomized
clinical trials.
Quality of evidence: Good.
Estimated Effect Size for
Pain (SMD): 0.07 (0.32e0.46)31.
Function (SMD): 0.34 (0.14e0.54)31.Weight management
Recommendation:
 Appropriate
Rationale:
A 2007 SR and meta-analysis found reductions in pain and
physical disability for overweight participants with knee OA after a
moderate weight reduction regime33. The analysis supported the
notion that aweight loss of 5% should be achievedwithin a 20-week
perioddthat is, 0.25% perweekdfor the treatment to be efﬁcacious.
Quality assessment:
Level of overall evidence: SR and meta-analysis of RCTs.
Quality of overall evidence: Good.
Estimated Effect Size for
Pain (SMD): 0.20 (0.0e0.39)33.
Function (SMD): 0.23 (0.04e0.42)33.
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Recommendation:
 Uncertain: knee-only OA
 Not appropriate: multiple-joint OA
Rationale:
Two 2010 SRs suggested a possible beneﬁcial effect of ultra-
sound for knee OA; however, the quality of the analyzed evidence
was low34,35. No safety risks were reported to be associated with
ultrasound. A 2012 RCT found no signiﬁcant differences between
the groups for pain or function36.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for Pain (SMD): Ranges from 0.49 (0.18e
0.79)35 to 0.49 (0.23e0.76)34.Pharmacological interventions
Acetaminophen (paracetamol)
Recommendation:
 Appropriate: individuals without relevant co-morbidities
 Uncertain: individuals with relevant co-morbidities
Rationale:
A 2010 SR and meta-analysis abstract found a low-level effect of
acetaminophen for OA pain, suggesting usefulness as a short-term
analgesic37. However, both this review and a 2012 safety review
indicated increased risk of adverse events associated with acet-
aminophen use, including GI adverse events and multi-organ fail-
ure38. These recent ﬁndings suggest greater risk associated with
acetaminophen use (particularly when used for extended dura-
tions) than previously thought. Thus, we recommend conservative
dosing and treatment duration consistent with approved pre-
scribing limits.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for Pain (SMD): 0.18 (0.11e0.25)37.Avocado soybean unsaponﬁables (ASU)
Recommendation:
 Uncertain
Rationale:
A 2008 SR and meta-analysis comparing ASU with oral placebo
in 644 patients with knee and hip OA demonstrated a small beneﬁt
for pain in favor of ASU that was more evident in knee OA39.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for Pain (SMD): 0.39 (0.01e0.76)39.
Capsaicin
Recommendation:
 Appropriate: knee-only OA without relevant co-morbidities
 Uncertain: multi-joint OA and individuals with relevant co-
morbidities
Rationale:
Citing a previous SR40 and RCT41, a 2011 comparative efﬁcacy
review concluded that topical capsaicin was superior to placebo for
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with increased local adverse events [54% vs 15%; relative risk (RR)
3.6 (95% CI: 2.6e5.0)] and withdrawals due to adverse events [13%
vs 3%; RR 4.0 (95% CI: 2.3e6.8)]42.
Quality assessment:
Level of evidence: SR of RCTs.
Quality of evidence: Good.
Estimated Effect Size for Pain and Physical function: Not
available.
Corticosteroids (intra-articular injection)
Recommendation:
 Appropriate
Rationale:
Two recent SRs demonstrated clinically signiﬁcant short-term
decreases in pain43,44. Short-term effects were found to be signiﬁ-
cantly greater than those of intra-articular hyaluronic acid. The
reviews concluded that for longer duration of pain relief, clinicians
should consider other treatment options.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for Pain: Not available.Chondroitin (for symptom relief)
Recommendation:
 UncertainChondroitin (for disease modiﬁcation)
Recommendation:
 Not appropriate
Rationale:
Four SRs examined the efﬁcacy of chondroitin for knee
OA45e48. Results differed regarding symptom relief, with some
reviews ﬁnding no signiﬁcant beneﬁt of chondroitin over pla-
cebo for pain and others ﬁnding large effect sizes in favor of
chondroitin. A high degree of heterogeneity and small, poor
quality included trials in one meta-analysis made deﬁnitive
assessment difﬁcult46. Effect sizes for pain were small to non-
existent [e.g., 0.01 (95% CI: 0.07e0.13)] in stratiﬁed analyses
of large-scale, high-quality trials46. Another meta-analysis
showed no statistically signiﬁcant beneﬁt of chondroitin when
compared with placebo45. Results were also mixed regarding
disease modiﬁcation, with only some studies showing statisti-
cally signiﬁcant decreases in joint-space narrowing (JSN) over
longer (2-year) follow-up47,48.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for Pain (SMD): Ranges from 0.13 (0.00e
0.27)45 to 0.75 (0.50e0.99)46.
Estimated Effect Size for reduction in rate of decline of
minimumjoint-spacewidth (SMD): Ranges from0.26 (0.14e0.38)47
to 0.30 (0.00e0.59)48.
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Recommendation:
 Uncertain
Rationale:
A 2010 SR and meta-analysis found a small but statistically
signiﬁcant short-term beneﬁt of diacerein for pain compared with
placebo, despite a large degree of heterogeneity among included
trials49. The review also found a signiﬁcantly increased risk of
diarrhea among those receiving diacerein [RR¼ 3.51 (95% CI: 2.55e
4.83, P < 0.001)]. The study authors suggested that diacerein may
still be a safer alternative to NSAIDs, which are associated with
more severe adverse events, but also concluded that more high-
quality trials are needed to conﬁrm the efﬁcacy of diacerein and
rule out publication bias.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for
Pain (SMD): 0.24 (0.08e0.39)49.
Function (SMD): 0.14 (0.03e0.25)49.
Duloxetine
Recommendation:
 Appropriate: individuals without co-morbidities
 Appropriate: individuals with multiple-joint OA and relevant
co-morbidities
 Uncertain: knee-only OA with relevant co-morbidities
Rationale:
A 2012 SR and a 2011 RCT comparing duloxetine with oral pla-
cebo found duloxetine efﬁcacious and tolerable for chronic pain
associated with OA50,51. Pooled analysis found that 16.3% of the
patients who received duloxetine withdrew due to adverse events
compared with 5.6% of those receiving placebo50. The most
commonly reported adverse events included nausea, dry mouth,
somnolence, fatigue, constipation, decreased appetite, and hyper-
hidrosis. While duloxetine was considered appropriate for mostclinical sub-phenotypes, associated adverse events and availability
of more targeted therapies predicated uncertain appropriateness
for individuals with knee-only OA and co-morbidities.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Fair.
Estimated Effect Size for Pain: Not available.
Glucosamine (for symptom relief)
Recommendation:
 UncertainGlucosamine (for disease modiﬁcation)
Recommendation:
 Not appropriate
Rationale:
Two SRs comparing glucosamine with placebo for OA found
mixed results regarding the efﬁcacy of glucosamine for pain relief
and physical function45,52. One review found no statistically sig-
niﬁcant beneﬁt of glucosamine for pain45 and the other found a
positive effect for pain that did not reach statistical signiﬁcance
when conﬁned to studies with adequate allocation concealment52.
The most recent meta-analysis45 included a large, NIH-funded RCT
(GAIT study) that had a null result for glucosamine for pain relief53.
Regarding disease modiﬁcation, a SR found no statistically signiﬁ-
cant differences in minimum JSN between glucosamine and pla-
cebo at 1-year follow-up, though a moderate effect was detected at
3 years48. A 2011 safety review found that long-term use of
glucosamine was not associated with cardiovascular (CV) safety
risks54. Two more meta-analyses found no increase in overall
adverse events relative to placebo45,52. Small pooled effect sizes
(especially for the large high-quality studies), inconsistency in re-
sults between industry-sponsored and independent trials, and
heterogeneity among studies generated uncertainty as to the
appropriateness of glucosamine.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
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Estimated Effect Size for Pain (SMD): Ranges from 0.17 (0.05,
0.28)45 to 0.47 (0.23e0.72)52.
Estimated Effect Size for reduction in rate of decline of
minimum joint-space width (SMD): 0.08 (0.12e0.27)48.
Hyaluronic acid (intra-articular injection)
Recommendation:
 Uncertain: knee-only OA
 Not appropriate: multiple-joint OA
Rationale:
A recent SR demonstrated small but signiﬁcant efﬁcacy of
intra-articular hyaluronic acid for knee OA pain by week 4 with
a peak at week 8 (reaching moderate clinical signiﬁcance) and
residual beneﬁt until 24 weeks55. Another review found mod-
erate beneﬁts of IAHA for pain and physical function in knee OA,
though sensitivity analyses including larger trials or trials with
adequate blinding found only small effect size for pain56. A third
review comparing IAHA with intra-articular corticosteroids
(IACS) found that while IACS provided greater beneﬁt for pain 2
weeks after injection, IAHA provided greater beneﬁt at 12 and
26 weeks43. Inconsistent conclusions among the meta-analyses
and conﬂicting results regarding IAHA’s safety inﬂuenced panel
votes.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.Estimated Effect Size for
Pain (SMD): Ranges from0.37 (0.28e0.46)56 to 0.46 (0.28e0.65)55.
Physical function: 0.33 (0.22e0.43)56 to 0.31 (0.11e0.51)55.NSAIDs (oral non-selective NSAIDs)
Recommendation:
 Appropriate: individuals without co-morbidities
 Uncertain: individuals with moderate co-morbidity risk
 Not appropriate: individuals with high co-morbidity risk
Gastroprotection:
 We do not recommend proton-pump inhibitor (PPI) co-
prescription with non-selective oral NSAIDs for those with no
co-morbidity risk. For thosewithmoderate or high co-morbidity
risk receiving oral non-selective NSAIDs, we recommend PPI co-
prescription, though we strongly advise against using oral
NSAIDs altogether for individuals with high co-morbidity risk.
Rationale:
A 2011 comparative effectiveness review indicated that NSAIDs
are associated with increased risk of serious GI, CV, and renal harms
compared with placebo42. Nevertheless, the CV safety of naproxen
appeared moderately superior to that of any COX-2 selective NSAID
in two SRs of RCTs. Among currently marketed NSAIDs, diclofenac is
associated with the highest rate of hepatic laboratory abnormal-
ities. Due to serious safety risks associated with oral NSAID use, we
recommend conservative dosing and treatment duration consistent
with approved prescribing limits.
The 2011 Cochrane review found that co-prescribing of PPIs,
misoprostol, and H2-antagonists reduced the risk of endoscopically
detected gastroduodenal ulcers compared with placebo in persons
prescribed non-selective NSAIDs42.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for Pain (SMD): 0.37 (0.26e0.49)57.
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 Appropriate: individuals without co-morbidities
 Appropriate: multiple-joint OA with moderate co-morbidity
risk
 Uncertain: knee-only OA with moderate co-morbidity risk
 Not appropriate: individuals with high co-morbidity risk
Gastroprotection:
 We do not recommend PPI co-prescription with COX-2 selective
oral NSAIDs for those with no co-morbidity risk. For individuals
with moderate co-morbidity risk, we advocate neither for
nor against PPI co-prescription. For individuals with high
co-morbidity risk receiving oral COX-2 selective NSAIDs, we
recommend PPI co-prescription, though we strongly advise
against using oral NSAIDs altogether for such individuals.Rationale:
A 2011 comparative effectiveness review found that relative
to non-COX-2 selective NSAIDs, selective COX-2 inhibitors were
better or comparably tolerated, though rates of serious adverse
events were similar42. Celecoxib was associated with a lower
risk of ulcer complications (RR 0.23, 95% CI: 0.07e0.76)
compared with non-selective NSAIDs but a moderately higher
risk of CV complications. Due to serious safety risks associated
with oral NSAID use, we recommend conservative dosing and
treatment duration consistent with US approved prescribing
limits.
Quality assessment based on Chou et al.42 and Lee et al.57:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for Pain: 0.44 (0.33e0.55)57.
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Recommendation:
 Appropriate: individuals with knee-only OA
 Uncertain: individuals with multiple-joint OA
Rationale:
A 2011 Cochrane comparative effectiveness review found com-
parable efﬁcacy of topical and oral NSAIDs for knee OA42. Topical
NSAIDs were associated with lower risk of GI adverse events but
higher risk of dermatological adverse events compared with oral
NSAIDs. Overall, topical NSAIDs were considered to be safer and
better tolerated compared with oral NSAIDs.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for Pain: Not available.Opioids (transdermal)
Recommendation:
 Uncertain
Rationale:
A 2009 SR and meta-analysis examining the efﬁcacy of opioids
for knee and hip OA found small effect sizes for pain and physical
function for transdermal fentanyl58. Patients receiving some form
of opioid therapy were four times as likely as patients receiving
placebo to withdraw due to adverse events (RR 4.05, 95% CI: 3.06e
5.38) and more than three times as likely to experience a serious
adverse event (RR 3.35, 95% CI: 0.83e13.56). Thus, the study
concluded that opioids offered limited usefulness in the long term.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for Pain (SMD): Ranges from 0.22 (0.03e
0.42) to 0.36 (0.26e0.47)58.Opioids (oral)
Recommendation:
 Uncertain
Rationale:
Analyses of pain relief from a 2009 SR found a moderate effect
size for codeine over placebo, a small to moderate beneﬁt for
oxycodone, and a small beneﬁt for morphine in patients with OA of
the knee or hip58. A 2006 review also found a small but statistically
signiﬁcant beneﬁt for tramadol over placebo59. However, patients
receiving some form of opioid therapy were four times as likely as
patients receiving placebo to withdraw due to adverse events (RR
4.05, 95% CI: 3.06e5.38) and more than three times as likely to
experience a serious adverse event (RR 3.35, 95% CI: 0.83e13.56)58.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for Pain: Ranges from 0.36 (0.26e0.47) to
0.51 (0.01e1.01)58.
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Recommendation:
 Not appropriate
Rationale:
Risedronate was evaluated primarily on its disease-modifying
efﬁcacy, as the majority of available evidence targets this
outcome. A 2012 SR found that higher doses of risedronate (15 mg/
d) did not reduce the signs or symptoms of OA, but did reduce the
marker of cartilage degradation (CTX-II), which may contribute to
attenuation of radiological progression of OA60. The review
concluded that further RCTs would be needed to assess the efﬁcacy
of risedronate for symptoms, function, and progression of knee OA.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Poor.
Estimated Effect Size for Pain: Not available.Rosehip
Recommendation:
 Uncertain
Rationale:
A 2008 SR and meta-analysis of three small trials found a
positive effect of rosehip powder for pain when compared with
placebo, but the reviewers concluded that further evaluation in
larger-scale trials is necessary due to the paucity of available
data61. Safety results from one included study did not provide
conclusive results.
Quality assessment:
Level of evidence: SR and meta-analysis of RCTs.
Quality of evidence: Good.
Estimated Effect Size for Pain: 0.37 (0.13e0.60)61.Discussion
These OARSI 2013 guidelines for the management of knee OA
represent an update to the previous OARSI publications in 2010 and
20081,2 and used the original evidence and set of evaluated treat-
ments as the base for a literature update. Their purpose is to
disseminate a framework for treatment of knee OA to professionals
involved in the management of this disorder, as well as patients,
provider organizations and regulatory bodies. The guidelines were
also developed for an International context, reﬂecting the constit-
uency and perspective of OARSI, the sponsoring organization. These
guidelines should be used in conjunction with individual patients’
values and clinical judgment.
We used the RAND/UCLA approach as a methodology for
measuring expert opinion and reaching a classiﬁcation for appro-
priateness of each treatment modality4. This well-established
approach leverages expert opinion in relation to their synthesis of
contemporary evidence. One advantage for the ﬁeld of OA treatment
is that it was explicitly developed to measure expert opinion in sit-
uations where the evidence may be incomplete. The outcome of the
voting process, according to this methodology, is a designation for
each putative therapy of “Appropriate,” “Uncertain” or “Inappro-
priate.” Among these, the implication of the term “Uncertain” was
viewed as unclear by reviewers. To clarify, the “Uncertain” classiﬁ-
cation is not intended here to be a negative recommendation or to
preclude use of that therapy. Rather it requires a role for physiciane
patient interaction in determining whether this treatment may have
merit in the context of its risk-beneﬁt proﬁle and the individual
characteristics, co-morbidities and preferences of the patient.
Our guidelines diverge from the previous OARSI guidelines in
2010 and 2008 as well as from recent American College of Rheu-
matology (ACR) and European League Against Rheumatism
(EULAR) guidelines by focusing speciﬁcally on treatment of OA of
the knee. The decision was made to examine knee OA separately
due to disparities in available evidence between hip OA and knee
OA and differences in best treatment practices between these
conditions. The current guidelines aim to identify the best-available
treatment practices for knee OA, irrespective of differing healthcare
policies and treatment standards internationally. Thus, this update
of the OARSI guidelines also excluded cost effective analysis, eval-
uating treatments solely based upon their safety and efﬁcacy
proﬁles.
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of four clinical sub-phenotypes. These were assessed separately in
order to best capture heterogeneous health proﬁles and OA disease
types. One limitation of this method is that the research literature
was not surveyed for OA sites beyond the knee and hip. Thus,
recommendations for individuals with multiple-joint OA may not
take into account all evidence regarding other joint sites. Expert
opinion of the OAGDG panel was used to support recommendations
in these instances. However, these guidelines’ recommendations
pertain to treatment of knee OA speciﬁcally, even when making
recommendations for individuals with OA in multiple-joint sites.
For all considered treatments, best-available evidence of efﬁcacy
and safety in knee OA was evaluated.
Our expert panel (OAGDG) represented a range of clinical dis-
ciplines that included rheumatologists (NA, FB, GH, DH, KK, TM, FR),
orthopedic surgeons (HK, SL), a primary care physician (MU),
physical therapists (SBZ, ER), a physiatrist (YH), and a clinical
epidemiologist (TM) (Appendix 1). The OAGDG also solicited
ongoing input from a patient advocate (RK), who attended the April
2013 OAGDG meeting and provided continuing feedback and
oversight via the development group’s online discussion forum.
Our team also included an evidence-basedmethodologist (RB) who
organized the development of the evidence report used by the
OAGDG panel. Panel voting was conducted with oversight from
OARSI’s Ethics Committee. OAGDG members with perceived
ﬁnancial conﬂicts of interest were recused from voting following
written and oral disclosures, with ﬁnal decisions made by an Ethics
Committee representative present at the OAGDG’s April 2013 face-
to-face meeting. Despite recusals, a majority of practicing clinicians
were present within the voting at all times. Thus, the results of
voting are unlikely to have lacked sufﬁcient voter expertise for any
treatment.
The present statement also incorporated treatments not
addressed in the prior OARSI guidelines such as risedronate and
duloxetine. Treatments such as ASU, rosehip, electrotherapy, and
ultrasound were not included in the 2008 OARSI recommendations
but have since been discussed in the 2010 evidence update and
assessed within our current guidelines. The present guidelines
focused primarily on the non-surgical management of knee OA,
though we recommend referral for consideration of orthopedic
surgical interventions after more conservative treatment options
have been exhausted. To examine the symptomatic slow-acting
drug for OA (SYSDOA) effect, glucosamine and chondroitin were
assessed separately for disease modiﬁcation and for symptom re-
lief. Other treatments received one score for overall efﬁcacy, as
other treatments were judged to lack sufﬁcient evidence to merit
separate assessment for disease modiﬁcation effect and symp-
tomatic effect.
In comparison to the previous OARSI guidelines published in
2008, recommendations for some treatments have changed.
Though the method of assessing treatment appropriateness has
changed between guidelines versions, complicating straightfor-
ward comparison, it nevertheless appears that recent evidence has
increased safety concerns regarding use of treatments such as
acetaminophen and opioids (both oral and transdermal), while
evidence for use of treatments such as duloxetine, balneotherapy,
and land-based exercises such as t’ai chi has strengthened. These
differences are updates to previous OARSI guidelines following the
development of new treatment options and greater available evi-
dence for existing treatments.
While many of the recommendations in this guidelines state-
ment agree with those published in other OA guidelines, our rec-
ommendations differ notably from others in a number of ways.
Although our recommendations are based on best-available evi-
dence, the current evidence contains some areas of inconsistency.With regard to non-pharmaceutical treatments, our recommenda-
tions were largely similar to other recent guidelines published by
the American Academy of Orthopaedic Surgeons (AAOS), ACR, and
EULAR, consistently recommending exercise programs for in-
dividuals with knee OA as well as weight loss programs for over-
weight individuals with knee OA. For this guidelines statement,
exercise modalities were divided into three groups (land-based,
water-based, and strength training) to provide greater speciﬁcity
than other OA guidelines in assessing their distinct beneﬁts and
risks and to evaluate their relative appropriateness for different
clinical sub-phenotypes. In other areas of non-pharmacological
treatment, our guidelines differed more substantially from others.
For electrotherapeutic modalities, AAOS provided an “Inconclusive”
recommendation, while these guidelines recommend against the
use of TENS and provide an “Uncertain” recommendation for EMG-
biofeedback.While ACR conditionally recommends acupuncture for
knee OA, and AAOS does not recommend acupuncture, our guide-
lines provide an “Uncertain” recommendation regarding acupunc-
ture, highlighting the lack of strong available evidence regarding its
use. Recommendations regarding biomechanical interventions
were also mixed; AAOS provided an inconclusive recommendation
regarding force braces, and both AAOS and EULAR recommended
against the use of wedged insoles, while ACR conditionally recom-
mended the use of medially wedged insoles. Rather than providing
recommendations individually for speciﬁc biomechanical modal-
ities, these guidelines recommend the use of biomechanical in-
terventions as directed by an appropriate specialist.
With regard to pharmaceutical treatment modalities, our guide-
lines also differ from others in several areas. AAOS’s 2013 guidelines
provided “Inconclusive” recommendations for both acetaminophen
and intra-articular corticosteroids, citing for IACS a “lack of
compelling evidence that has resulted in an unclear balance between
beneﬁts and potential harm.” In contrast, our guidelines coincide
with ACR’s 2012 guidelines in recommending both APAP (for those
without relevant co-morbidities) and IACS as appropriate, ﬁnding
the potential beneﬁts to outweigh associated risks in certain clinical
scenarios. Regarding glucosamine and chondroitin, AAOS recom-
mended against use of both treatments and ACR recommended
against chondroitin and conditionally against glucosamine. Our
guidelines provide greater speciﬁcity than previous guidelines by
evaluating these treatments separately for symptomatic relief and
disease modiﬁcation. Our group responded more favorably (voting
“Uncertain”) for the symptomatic efﬁcacy of each of these two
treatments than for the disease-modifying use of each (voting “Not
appropriate”). The contrasting assessments of glucosamine and
chondroitin’s symptomatic versus disease-modifying efﬁcacy may
indicate the source of some of the inconsistency in the perceived
value of these treatments among other recent guidelines. Regarding
hyaluronic acid treatment, AAOS recommended against the use of
IAHA, citing a lack of efﬁcacy. Our guidelines offer a stance similar to
that of ACR, providing an “Uncertain” recommendation for IAHA for
individuals with knee-only OA. Despite safety and efﬁcacy concerns
of IAHA raised by one meta-analysis, a number of analyses revealed
positive effect sizes for pain. Oral NSAIDs (both non-selective and
COX-2 selective) were conditionally recommended by ACR, which
was also reﬂected in our guidelines through the use of clinical sub-
phenotypes. Conversely, AAOS strongly recommended both oral
and topical NSAIDs. ACR guidelines conditionally recommend
against topical capsaicin use, while we considered it appropriate in
patients without relevant co-morbidities. Finally, the ACR provided
negative or uncertain recommendations for the use of duloxetine,
while these guidelines considered duloxetine appropriate for those
without co-morbidities and those with multiple-joint OA and pro-
vided an “Uncertain” recommendation for duloxetine in individuals
with knee-only OA and co-morbidities.
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addressed. These guidelines were developed based on the previ-
ous guidelines report and expanded where the OAGDG felt sufﬁ-
cient new evidence was available to merit inclusion (based on
number and quality of available trials). Our guidelines did not
consider treatments included in the previous OARSI 2010 guide-
lines such as vitamin E and calcitonin, as well as interventions
included in the AAOS guidelines, such as platelet-rich plasma
therapy and growth factor injections. Treatment duration and
duration of beneﬁt were not voted on separately for limited versus
extended course for pharmaceutical treatments due to the lack of
clarity in available evidence. Other treatments not included in our
guidelines include lavage and debridement (considered for inclu-
sion but removed due to consistent evidence of ineffectiveness),
strontium (recently received a recommendation to restrict use by
the European Medicines Agency and not approved by US FDA)62,
and licofelone (not currently approved by the European Medicines
Agency or US FDA). Manual therapy was not included in these
guidelines due to insufﬁcient available evidence. Unlike ACR, we
did not include patellar taping or psychosocial intervention for
knee OA. However, our guidelines also contain many treatment
modalities not addressed by other (ACR) guidelines, such as ASU,
risedronate, diacerein, and rosehip. In addition, these guidelines
divided various treatments (e.g., NSAIDs, opioids, and exercise)
into sub-categories to better assess considerations such as delivery
method, drug mechanism or other factors, aiming to provide
speciﬁc and actionable treatment recommendations. Our guide-
lines are also unique in that the recommendations considered the
risk, beneﬁt, and appropriateness of each treatment individually
for the speciﬁc sub-phenotypes described in our methods. One
limitation of these categories is that not every treatment had
available research for all clinical sub-phenotypes. In such cases,
expert consensus was relied upon via the RAND/UCLA voting
method. The role of expert opinion and voters’ enthusiasm for
treatment modalities may also explain some instances where the
panel’s voting diverged from effect sizes presented in the evi-
dence. The four clinical sub-phenotypes were assessed separatelyAppendix 1
Disclosure of potential conﬂicts of interest
Name & specialty
(in author-list
order)
Consulting fees, honoraria,
research or institutional
support, educational grants,
equipment, services or
expenses
Research grants/contracts
T. McAlindon
Rheumatologist;
Epidemiologist
Flexion
TherapeuticsjConsulting,
SamumedjConsulting,
AbbviejConsulting,
SanoﬁjConsulting,
MyrtusjLicensing fee
NIH, Croma
R. Bannuru None AHRQjF32 HS021396 gran
M. Sullivan None None
N. Arden*
Rheumatologist
MerckjConsultancy,
RochejConsultancy, Smith
and NephewjConsultancy,
PﬁzerjSpeaker Bureau,
FlexionjConsultancy,
BioibericajConsultancy,
Speaker bureau
NIHRjOutcomes of Arthrop
and Biomedical Research U
NIHjHip morphology,
ARUKjVIDEO, project and
equipment grants
F. Berenbaum*
Rheumatologist
PﬁzerjAdvisory board,
ExpansciencejAdvisory
board, UCBjAdvisory board,
ServierjAdvisory board,
research support,
Agence Nationale Rechercfor every treatment considered in order to best capture hetero-
geneous health proﬁles and OA disease types.
Conﬂict of interest
Full disclosure statements from all members of the OARSI Guide-
lines Development Group are shown in Appendix 1. These were
reviewed by the OARSI Ethics Committee. No potential conﬂicts of
interest were identiﬁed that should preclude any member of the
committee participating in this critical appraisal. No OAGDG
members are employees of any pharmaceutical or medical device
company. OAGDG members were recused from voting on select
treatments where potential conﬂicts arose, as described in the
report Methodology section. Corporate members of OARSI are also
listed in Appendix 1. The data extraction team included ﬁve
members of the Division of Rheumatology, Tufts Medical Center,
Boston, MA, USA: Raveendhara Bannuru MD, FAGE, Elizaveta
Vaysbrot, MD, Matthew Sullivan, BA, Elena Manning, BS, and Bryan
Bourdeau, BS. Dr Bannuru is supported by a F32 HS021396 grant
from the Agency for Healthcare Research and Quality. The content
is solely the responsibility of the authors and does not necessarily
represent the ofﬁcial views of the Agency for Healthcare Research
and Quality. Elizaveta Vaysbrot, Matthew Sullivan, Elena Manning,
and Bryan Bourdeau have no conﬂicts of interest to disclose.
Role of the funding source
These guidelines were commissioned by the OARSI and sponsored
by a grant from OARSI. This report is endorsed by the Board of
Directors of OARSI; it was developed independently by the OARSI
Guidelines Development Group.
Acknowledgments
The authors would like to thank Elizaveta Vaysbrot and Elena
Manning for data collection and Diann Stern for logistics support
throughout the project. We thank patient representative Robin
Katzanek for her guidance. Financial support for data collection at
Tufts Medical Center came from an OARSI grant.Service with organization with
interests comparable to OARSI
Recused from voting on the
following treatment modalities
Co-editor for Arthritis &
Rheumatism
Hyaluronic acid
t None Not a voter
None Not a voter
lasty
nit,
None Chondroitin
Hyaluronic acid
All surgery
he French Society of
Rheumatology
NSAIDs
(continued on next page)
Appendix 1 (continued )
Name & specialty
(in author-list
order)
Consulting fees, honoraria,
research or institutional
support, educational grants,
equipment, services or
expenses
Research grants/contracts Service with organization with
interests comparable to OARSI
Recused from voting on the
following treatment modalities
symposium, TRB
Chemedicajresearch
support, SanoﬁjAdvisory
board, AbbottjAdvisory
board
S. Bierma-
Zeinstra*
Physical therapist;
Epidemiologist
S. Bierma-Zeinstra
(disclosure
cont’d)
None Dutch Arthritis
Associationjresearch in
corticosteroids for OA, OA
vascular pathology, early OA
diagnosis, brace vs osteotomy
treatment, & OA stepped care;
The Netherlands Organization
for Health Research and
Developmentjresearch in
identiﬁcation, prevention of
knee OA, OA phenotyping,
treatment cost-effectiveness
(ACL rupture,
viscosupplementation, surgery
vs conservative treatment in
lumbar stenosis),
corticosteroids for trochanteric
pain syndrome, ankle injury
complications, exercise after
injury, & exercise therapy for
patellofemoral pain syndrome;
Nuts Ohrajresearch in X-ray OA
diagnosis, OA pain medication,
& statines & OA; EU
FP7jmarkers for early detection
& progression of OA
None Glucosamine
G. Hawker*
Rheumatologist
Women’s College
HospitaljPhysician in Chief
of MedicinejSalary Support
Award, Women’s College
Hospital FoundationjFM
Hill Chair in Academic
Women’s Medicine.
Nothing to declare
Operating grants from the
Canadian Institutes of Health
ResearchjCanadian Arthritis
NetworkjCochrane
Collaboration/writing paper
with Adelphi, a marketing
companywhoworked for Pﬁzer
on a survey of physicians
regarding factors that inﬂuence
their perceptions of OA severity
e unpaid
None None
Y. Henrotin*
Physical therapy &
rehabilitation
Bioiberica; BioXtract;
Danone; Nestle; Pierre
Fabre; Grunenthal;
Expanscience; Artialis;
Tilman; Merck;
IbsajHonoraria. Patent
ownership:
ArtialisjBiomarkers; Kit
immunoassaysj
Development &
commercialization of
biomarkers of cartilage
degradation &
inﬂammation
Walloon Government-
BelgiumjFirst Post-Doc RW/
5291 PROMART-Recherche de
nouveaux biomarqueurs (2007
e2009).165.765; First Post-Doc
RW/716609 CARTIMAT:
Recherche de nouveaux
biomateriaux; FIRST Entreprise
- 73.726,4 Euros, European
commissionjFP7 D-Board, rd;
Bioiberica &
Expansciencejunrestricted
educational grants
None Chondroitin
D. Hunter*
Rheumatologist
DonJoyjRoyalties;
Merck SeronojConsulting,
Flexion
TherapeuticsjConsulting
Australian Research
CounciljFuture Fellowship,
NIHjPOMA, NHMRCjproject
grants
Bone and Joint Decade
International Coordinating
Council, Advisory editor for
Arthritis Care and Research,
Associate Editor for
International Journal of
Rheumatic Diseases
Biomechanical interventions
H. Kawaguchi*
Orthopedic surgeon
Teijin Pharma Co.,
Ltd.jConsulting fee
None BMC Musculoskeletal
DisordersjAssociate Editor,
Japanese Orthopaedic
AssociationjCommittee
Member, Japanese Society for
Bone and Mineral
MetabolismjCommittee
Member, Journal of
Hyaluronic acid
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Name & specialty
(in author-list
order)
Consulting fees, honoraria,
research or institutional
support, educational grants,
equipment, services or
expenses
Research grants/contracts Service with organization with
interests comparable to OARSI
Recused from voting on the
following treatment modalities
Orthopaedic SciencejEditorial
Board, Journal of Bone &Mineral
MetabolismjEditorial Board,
Japanese Society of Cartilage
MetabolismjComm. Member
R. Katzanek
Patient advocate
Nothing to declare None None N/A
K. Kwoh
Rheumatologist
NovartisjAdvisory Board
and DSMB, NIHjDSMB,
Express ScriptsjConsulting,
PﬁzerjRA Quality Measures
Roundtable
NIHjNIAMS P60AR054731 PITT-
MCRC for rheumatic and
musculoskeletal diseases;
NIAMS N01AR-2-2260 Clinical
centers for the Osteoarthritis
Initiative; NHLBI
HHSN26820100002 Pivotal OAI
MRI Analyses (POMA); NIAMS
R01AR056630 Single- vs
Double-Bundle ACL
Reconstruction: A Prospective
Randomized Trial; NINR
R01NR010904 Promoting
Physical Activity in Older Adults
with Co-morbidity;
CDCjU48DP001918 Health
Promotion and Disease
Prevention Research Center
Arthritis FoundationjPublic
Health Committee
Glucosamine
Risedronate
S. Lohmander*
Orthopedic surgeon
Merck SeronojAdvisory
board, Informed Medical
Decision MakingjSpeaker
honorarium, Össur
Advisory Board, Abbott
Consultancy, Flexion
Therapeutics Advisory
Board, Allergan
Consultancy, Medivir
Consultancy, Merrimack
Pharmaceuticals
Consultancy, Servier
Consultancy
Swedish Research CounciljLund
University, Swedish
Rheumatism AssociationjLund
University, Medical
facultyjLund University
None Biomechanical interventions
F. Rannou*
Rheumatologist
Sanoﬁ Aventis, Pﬁzer,
Rottapharm, Pierre Fabre,
Genzyme, Merck,
Genévrier, Expanscience,
Negma, ServierjConsulting/
Advisory board
AP-HPjNon-pharmacological
treatments in rheumatic
diseases, GSKjHO-1 inducer
molecules in cartilage,
Fondation de
l’AvenirjMolecular mapping of
IVD in scoliosis
Member of the Eular Scientiﬁc
Committee
NSAIDs
Hyaluronic acid
ASU
Diacerein
E. Roos*
Physical therapist
National Welfare Board,
SwedenjReviewer, National
board for preventive
medicine, DenmarkjBoard
member, ÖssurjLecture
fees, Finnish Orthopedic
SocietyjLecture fees,
StudentlitteraturjRoyalties,
MunksgaardjRoyalties,
Osteoarthritis and
CartilagejAssociate Editor
Southern Health Care Region,
DenmarkjRCT on exercise vs
pharma, Danish Rheumatism
AssociationjKnee OA
prevention and treatment
None None
M. Underwood
Primary care
practitioner;
primary care
research
Travel, Accommodation
and Conference fee waiver
from OARSI to attend
OAGDG meetings
concurrent with annual
scientiﬁc meeting
NIHR Programme
grantsjImproving outcomes
from the treatment of back
pain; Improving self-
management of chronic pain,
NHS HTA
ProgrammejPrevention of Fall
Injury Trial (Pre-FIT);
Adherence to strengthening
activities in rheumatoid
arthritis of the hand (SARAH);
Older People’s Exercise
intervention in Residential and
nursing Accommodation
National Institute for Health
and Care Excellence (NICE)j
Chair of Headache Guideline
Development Group (2010
e12).
Chair NICE Accreditation
Advisory Committee (2013)
NICE Strategy Board, in
attendance (2013)
Acupuncture
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Name & specialty
(in author-list
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Consulting fees, honoraria,
research or institutional
support, educational grants,
equipment, services or
expenses
Research grants/contracts Service with organization with
interests comparable to OARSI
Recused from voting on the
following treatment modalities
(OPERA), National Centre for
Osteopathic
ResearchjInvestigating
osteopath’s attitudes to
managing and assessing risk in
clinical settings and patient’s
experiences and responses,
Research for Patient
BeneﬁtjImproving Patient
Choice in Treating Low Back
Pain (IMPACT - LBP).
NHS Health Technology
Assessment Programme. Facet
joint feasibility study.
OARSI’s Congress sponsors and corporate members for 2013 include the following: Bioiberica; EMD Serono; Expanscience; Rottapharm/Madaus; Abbvie; Astellas; Bio-
ventus; Boston Imaging Core Lab (BICL); Chondrometrics; Fidia Pharma USA, Inc.; Flexion; Perceptive Informatics; Merck; Seikagaku; Servier; Zimmer. No direct medical
industry support was used or requested for guideline development. Guidelines development was a budgeted item in OARSI’s annual budget.
* Panel member has an editorial position with the Osteoarthritis and Cartilage journal.
Appendix 3
Table A
Appropriateness voting data
Appropriateness scores
No co-morbidities Co-morbidities
Median Appropriate (Y/N/U) Disagreement? Median Appropriate (Y/N/U) Disagreement?
Non-pharmaceutical treatments
Acupuncture Knee 5 Uncertain No 4.5 Uncertain No
Multi-joint 4.5 Uncertain No 4.5 Uncertain No
Balneotherapy Knee 5 Uncertain No 6 Uncertain No
Multi-joint 6 Uncertain No 7 Yes No
Biomechanical interventions Knee 7 Yes No 7 Yes No
Multi-joint 7 Yes No 7 Yes No
Cane (walking stick) Knee 7 Yes No 7 Yes No
Multi-joint 6 Uncertain No 6 Uncertain No
Crutches Knee 6 Uncertain No 6 Uncertain No
Multi-joint 5 Uncertain No 5.5 Uncertain No
Electrotherapy/neuromuscular electrical stimulation Knee 3 No No 3 No No
Appendix 2
T.E. McAlindon et al. / Osteoarthritis and Cartilage 22 (2014) 363e388382
Table A (continued )
Appropriateness scores
No co-morbidities Co-morbidities
Median Appropriate (Y/N/U) Disagreement? Median Appropriate (Y/N/U) Disagreement?
Multi-joint 3 No No 3 No No
Exercise (land-based) Knee 8 Yes No 8 Yes No
Multi-joint 8 Yes No 8 Yes No
Exercise (water-based) Knee 7 Yes No 7 Yes No
Multi-joint 8 Yes No 8 Yes No
Strength training Knee 8 Yes No 8 Yes No
Multi-joint 8 Yes No 7 Yes No
Self-management and education Knee 8 Yes No 9 Yes No
Multi-joint 9 Yes No 9 Yes No
TENS Knee 5 Uncertain No 5 Uncertain No
Multi-joint 3 No No 3 No No
Weight management Knee 8 Yes No 8 Yes No
Multi-joint 8 Yes No 9 Yes No
Ultrasound Knee 4 Uncertain No 4 Uncertain No
Multi-joint 3 No No 3 No No
Pharmaceutical treatments
Acetaminophen (paracetamol) Knee 7 Yes No 6 Uncertain No
Multi-joint 7 Yes No 6 Uncertain No
ASU Knee 4 Uncertain No 4 Uncertain No
Multi-joint 5 Uncertain No 5 Uncertain No
Capsaicin Knee 7 Yes No 6 Uncertain No
Multi-joint 6 Uncertain No 6 Uncertain No
Corticosteriods (intra-articular injection) Knee 7 Yes No 7 Yes No
Multi-joint 7 Yes No 7 Yes No
Chondroitin: symptom relief Knee 5 Uncertain No 5 Uncertain No
Multi-joint 5 Uncertain No 5 Uncertain No
Chondroitin: disease modiﬁcation Knee 3 No No 3 No No
Multi-joint 3 No No 3 No No
Diacerein Knee 4 Uncertain No 4 Uncertain No
Multi-joint 4 Uncertain No 4 Uncertain No
Duloxetine Knee 7 Yes No 6 Uncertain No
Multi-joint 7 Yes No 7 Yes No
Glucosamine: symptom relief Knee 5.5 Uncertain No 5.5 Uncertain No
Multi-joint 5.5 Uncertain No 5.5 Uncertain No
Glucosamine: disease modiﬁcation Knee 3 No No 3 No No
Multi-joint 3 No No 3 No No
Hyaluronic acid (intra-articular injection) Knee 5 Uncertain No 4 Uncertain No
Multi-joint 3 No No 3 No No
NSAIDs (topical) Knee 8 Yes No 7 Yes No
Multi-joint 6 Uncertain No 6 Uncertain No
Opioids: transdermal Knee 4 Uncertain No 4 Uncertain No
Multi-joint 5 Uncertain No 4 Uncertain No
Opioids: oral Knee 5 Uncertain No 4 Uncertain No
Multi-joint 5 Uncertain No 6 Uncertain No
Risedronate Knee 3 No No 3 No No
Multi-joint 3 No No 3 No No
Rosehip Knee 5 Uncertain No 5 Uncertain No
Multi-joint 5 Uncertain No 5 Uncertain No
For each treatment modality, the OAGDG voted on appropriateness using a nine-point scale (1e9).
Deﬁnitions: No co-morbidities: The individual with OA has no pertinent co-morbid health concerns. Co-morbidities: The individual with OA has any of the following
pertinent co-morbid health concerns: diabetes; hypertension; CV disease; renal failure; GI bleeding; depression; or physical impairment limiting activity, including obesity.
Knee: Symptomatic OA in one or both knees only. Multi-joint OA: Symptomatic OA of the knee(s) in addition to other joints (e.g., hip, hand, spine, etc).
Disagreement: An appropriateness vote was considered to be in ‘disagreement’ if greater than one-third of votes fell in the opposite tertile to themedian score [e.g., a vote was
considered in “Disagreement” if it received an “Appropriate” median vote (7) with ﬁve of 13 members voting ”Not appropriate” (3)].
Table B
Risk scores, beneﬁt scores, and composite risk and beneﬁt scores
Risk scores Beneﬁt scores Beneﬁt and risk scores
No co-morbidities Co-morbidities No co-morbidities Co-morbidities No co-morbidities Co-morbidities
Mean (1e10) Mean (1e10) Mean (1e10) Mean (1e10) (1e100) (1e100)
Non pharmaceutical treatments
Acupuncture Knee 1.9 2.3 3.1 3.0 28.0 26.3
Multi-joint 1.9 2.3 3.1 3.0 28.0 26.3
Balneotherapy Knee 1.3 1.5 4.2 4.2 40.3 40.0
Multi-joint 1.3 1.6 4.5 4.5 43.2 41.9
Biomechanical interventions Knee 1.5 2.0 5.6 5.6 57.0 50.4
(continued on next page)
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Table B (continued )
Risk scores Beneﬁt scores Beneﬁt and risk scores
No co-morbidities Co-morbidities No co-morbidities Co-morbidities No co-morbidities Co-morbidities
Mean (1e10) Mean (1e10) Mean (1e10) Mean (1e10) (1e100) (1e100)
Multi-joint 1.6 2.1 4.7 4.7 37.6 41.8
Cane (walking stick) Knee 1.6 1.6 5.0 5.0 46.9 46.9
Multi-joint 1.8 1.8 4.2 4.0 38.3 36.9
Crutches Knee 1.7 1.7 4.4 4.3 40.8 40.1
Multi-joint 1.8 1.8 3.7 3.8 33.8 34.5
Electrotherapy/neuromuscular electrical stimulation Knee 2.0 2.1 2.5 2.4 22.2 21.3
Multi-joint 2.0 2.1 1.9 1.9 17.3 17.2
Exercise (land-based) Knee 1.2 1.9 6.6 6.8 64.6 61.4
Multi-joint 1.3 2.1 6.4 6.5 61.9 58.3
Exercise (water-based) Knee 1.5 2.3 5.9 6.2 56.0 54.2
Multi-joint 1.5 2.2 6.2 6.5 59.0 56.7
Strength training Knee 1.4 1.8 6.9 6.8 66.6 62.0
Multi-joint 1.6 2.2 6.0 6.0 56.3 53.1
Self management and education Knee 1.2 1.5 4.9 5.1 48.1 48.4
Multi-joint 1.2 1.5 5.2 5.2 50.3 49.5
TENS Knee 1.8 1.8 3.2 3.2 29.1 28.9
Multi-joint 1.8 1.8 2.4 2.4 22.0 21.8
Weight management Knee 1.2 1.5 6.1 6.3 59.4 60.2
Multi-joint 1.2 1.5 6.2 6.4 60.1 60.4
Ultrasound Knee 1.3 1.5 2.8 3.0 27.6 28.6
Multi-joint 1.4 1.4 2.4 2.5 22.9 24.4
Pharmaceutical treatments
Acetaminophen (paracetamol) Knee 3.4 4.5 4.5 4.4 34.0 28.3
Multi-joint 3.5 4.7 4.6 4.5 34.8 28.6
Avocado soybean unsaponﬁables Knee 1.6 1.8 3.5 3.5 33.2 32.6
Multi-joint 1.6 1.8 3.6 3.6 34.0 33.4
Capsaicin Knee 2.6 2.8 5.1 5.1 42.6 41.8
Multi-joint 2.9 3.1 4.7 4.7 37.9 37.2
Corticosteriods (intra-articular injection) Knee 2.8 3.6 6.5 6.4 53.8 47.1
Multi-joint 2.8 3.6 5.2 5.3 42.7 39.2
Chondroitin: symptom relief Knee 1.1 1.3 3.8 3.9 37.8 38.0
Multi-joint 1.1 1.3 3.8 4.0 37.8 38.9
Chondroitin: disease modiﬁcation Knee 1.1 1.3 2.7 2.7 27.0 26.5
Multi-joint 1.1 1.4 2.6 2.5 26.1 23.7
Diacerein Knee 3.8 4.0 3.7 3.7 26.6 25.7
Multi-joint 3.8 4.0 3.8 3.8 27.8 26.3
Duloxetine Knee 4.0 4.7 5.3 5.4 37.2 34.0
Multi-joint 4.0 4.7 5.6 5.6 39.3 35.4
Glucosamine: symptom relief Knee 1.4 1.7 3.9 3.9 37.4 36.3
Multi-joint 1.5 1.7 4.0 4.0 38.0 37.2
Glucosamine: disease modiﬁcation Knee 1.4 1.7 2.7 2.7 26.3 25.3
Multi-joint 1.4 1.7 2.5 2.5 24.5 23.6
Hyaluronic acid (intra-articular injection) Knee 3.1 3.8 4.1 4.2 32.4 30.5
Multi-joint 3.3 3.9 3.0 3.1 23.0 22.1
NSAIDs (topical) Knee 2.7 3.5 6.0 5.9 49.8 44.7
Multi-joint 2.9 3.8 5.2 5.2 42.2 36.9
Opioids: transdermal Knee 4.8 6.1 5.2 4.9 31.7 24.2
Multi-joint 4.9 6.1 5.3 5.1 32.3 25.0
Opioids: oral Knee 5.5 6.5 5.6 5.4 30.7 24.0
Multi-joint 5.6 6.5 5.7 5.4 30.7 24.0
Risedronate Knee 3.2 3.3 2.7 2.7 20.9 20.4
Multi-joint 3.2 3.3 2.8 2.7 21.5 20.4
Rosehip Knee 1.8 1.9 3.3 3.4 30.3 30.7
Multi-joint 1.8 1.9 3.3 3.4 30.3 30.7
For each treatment modality, the OAGDG voted on therapeutic beneﬁt on a 10-point scale (1e10) and overall risk on a 10-point scale (1e10). The composite beneﬁt and risk
score is the product of the beneﬁt score (1e10) and the transposed risk score (where 1 ¼ highest and 10 ¼ safety) yielding a range of 1 (worst) to 100 (best).
No co-morbidities: The individual with OA has no pertinent co-morbid health concerns. Co-morbidities: The individual with OA has any of the following pertinent co-morbid
health concerns: diabetes; hypertension; cardiovascular disease; renal failure; GI bleeding; depression; or physical impairment limiting activity, including obesity. Knee:
Symptomatic OA in one or both knees only. Multi-joint: Symptomatic OA of the knee(s) in addition to other joints (e.g. hip, hand, spine, etc).
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Oral NSAIDs voting data
Treatment OA type Appropriateness vote Voting disagreement? Percent voting in favor of gastroprotection
Co-morbidity risk Co-morbidity risk Co-morbidity risk
No co-morbidities Moderate
risk
High
risk
No co-morbidities Moderate
risk
High risk No co-morbidities Moderate risk High risk
Oral NSAIDs
(non-selective)
Knee-only OA 7.0 5.0 2.0 No No No 33% 92% 100%
Multi-joint OA 7.5 4.0 2.0 No No No 67% 92% 92%
Table C (continued )
Treatment OA type Appropriateness vote Voting disagreement? Percent voting in favor of gastroprotection
Co-morbidity risk Co-morbidity risk Co-morbidity risk
No co-morbidities Moderate
risk
High
risk
No co-morbidities Moderate
risk
High risk No co-morbidities Moderate risk High risk
Oral NSAIDs
(COX-2 inhibitors)
Knee-only OA 7.0 6.0 3.0 No No No 18% 50% 100%
Multi-joint OA 7.0 7.0 3.0 No No No 36% 50% 91%
Treatment OA Type Risk scores Beneﬁt scores Beneﬁt and risk scores
Co-morbidity risk Co-morbidity risk Co-morbidity risk
No co-morbidities Moderate
risk
High
risk
No co-morbidities Moderate
risk
High risk No co-morbidities Moderate risk High risk
Oral NSAIDs
(non-selective)
Knee-only OA 4.6 6.1 7.8 5.9 5.6 5.2 40.7 29.7 17.3
Multi-joint OA 4.6 6.1 7.8 6.2 5.6 5.3 42.8 30.9 18.6
Oral NSAIDs
(COX-2 inhibitors)
Knee-only OA 4.6 6.1 6.6 6.0 5.7 5.4 46.6 38.3 24.7
Multi-joint OA 3.8 4.7 6.6 6.4 6.1 5.8 46.8 38.8 25.4
For each treatment modality, the OAGDG voted on appropriateness using a nine-point scale (1e9), on therapeutic beneﬁt on a 10-point scale (1e10) and overall risk on a 10-
point scale (1e10). The composite beneﬁt and risk score is the product of the beneﬁt score (1e10) and the transposed risk score (where 1¼ highest and 10¼ safety) yielding a
range of 1 (worst) to 100 (best).
Deﬁnitions: No co-morbidities: The individual with OA has no pertinent co-morbid health concerns. Co-morbidities: The individual with OA has any of the following
pertinent co-morbid health concerns: diabetes; hypertension; CV disease; renal failure; GI bleeding; depression; or physical impairment limiting activity, including obesity.
Knee-only OA: Symptomatic OA in one or both knees only. Multi-joint OA: Symptomatic OA of the knee(s) in addition to other joints (e.g., hip, hand, spine, etc).
Disagreement: An appropriateness vote was considered to be in ‘disagreement’ if greater than one-third of votes fell in the opposite tertile to themedian score [e.g., a vote was
considered in “Disagreement” if it received an “Appropriate” median vote (7) with ﬁve of 13 members voting ”Not appropriate” (3)].
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